The Deadly Business of an Unregulated Global Stem Cell Industry by Lysaght, T et al.
1 
 
This is an Accepted Manuscript of an article published in [J Med Ethics] on 29 March 2017 available online at 
http://jme.bmj.com/content/early/2017/03/29/medethics-2016-104046.full.  
Self-archived in the Sydney eScholarship Repository by the Centre for Values, Ethics and the Law in Medicine 
(VELiM), University of Sydney, Australia 
Please cite as: 
Lysaght, T., Lipworth, W., Hendl, T., Kerridge I., Munsie, M., Waldby, C.,Stewart, C., The Deadly Business of an 
Unregulated Global Stem Cell Industry, Journal of Medical Ethics, Published online 29 March 2017. doi: 
10.1136/medethics-2016-104046  
The Deadly Business of an Unregulated Global Stem Cell 
Industry 
Tamra Lysaght1, Wendy Lipworth2, Tereza Hendl2, Ian Kerridge2,3, Tsung-Ling Lee1, Megan Munsie4, 
Catherine Waldby5, Cameron Stewart6 
 
1 Centre for Biomedical Ethics, Level 2 Block MD11, Clinical Research Centre, 10 Medical Drive, 
National University of Singapore, Singapore 117576. Email: tlysaght@nus.edu.sg. DID: +65 6516 
7903 
2 Centre for Values Ethics and the Law in Medicine, University of Sydney, Sydney Australia 
3 Haematology Department, Royal North Shore Hospital, Sydney Australia 
4 Stem Cells Australia, University of Melbourne, Melbourne Australia 
5 College of Arts and Social Sciences, Australian National University, Canberra Australia 
6 Sydney Law School, University of Sydney, Sydney Australia 
 
Abstract 
In 2016, the Office of the State Coroner of New South Wales released its report into the death of an 
Australian woman, Sheila Drysdale, who had died from complications of an autologous stem cell 
procedure at a Sydney clinic. In this report, we argue not only that Mrs Drysdale’s death was 
avoidable, but that it was the result of a pernicious global problem of an industry exploiting 
regulatory systems in order to sell unproven and unjustified stem cell interventions. 
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The Death of Sheila Drysdale 
In December 2013, the private Sydney clinic of cosmetic surgeon, Dr Ralph Bright, admitted 75-year 
old Sheila Drysdale for a liposuction procedure. Dr Bright did not perform this procedure for 
cosmetic reasons, but rather to ‘treat’ her advanced dementia with adipose-derived stem cells. 
Tragically, Mrs Drysdale died within ten hours of the procedure.  
According to the NSW Deputy Coroners’ Report,(1) Dr Bright had removed approximately 500ml of 
fat from Mrs Drysdale’s flanks and buttocks on the day of the intervention. This tissue was then 
“processed” in the clinic’s laboratory to derive “1.5 billion stem cells” for subsequent intravenous 
administration later that day. In the immediate post-operative period, Mrs Drysdale was noted to be 
drowsy and hypotensive. Even though Mrs Drysdale was being monitored and administered 
medications to assist in her recovery, she continued to deteriorate and died at her nursing home less 
than three hours after being discharged.  
The Deputy Coroner found that the cause of Mrs Drysdale’s death was hypovolemic shock due to 
uncontrolled blood loss following the liposuction procedure. He attributed the blood loss to Dr 
Bright’s failure to ensure that the patient had ceased her anti-platelet medication prior to the 
surgery. The Deputy Coroner was also critical of Dr Bright for failing to recognise or appropriately 
respond to clinical signs indicating post-operative blood loss; discharging Mrs Drysdale prematurely 
and, when it became clear that her condition had deteriorated, failing to recommend that she be 
taken to hospital for immediate treatment. 
Mrs Drysdale’s death, while unfortunate, resulted from a well-recognised complication of 
liposuction: the likelihood of death following liposuction is estimated to be between 3-100 per 
100,000 procedures.(2) What makes her death so profoundly tragic, however, is that it occurred as a 
complication of an intervention for which there is no scientific support. While there is some pre-
clinical data and (weak) evidence from clinical trials to suggest that autologous adipose-derived 
mesenchymal stem cells may have some benefit for the treatment of arthritis and other joint or 
muscular injuries,(3) there is no published scientific research that indicates any benefit for patients 
with dementia.(4, 5) 
This fact was not lost on the Deputy Coroner, who stated that the use of stem cells for dementia was 
“highly questionable” and that it displayed “some of the hallmarks of ‘quack’ medicine: desperate 
patients, pseudo-science and large amounts of money being charged for unproven therapies” (1). 
Consequently, the Coroner recommended an investigation into Dr Bright’s conduct and called for 
the relevant agencies to develop guidelines to regulate more rigorously “experimental” or 
“innovative” medical or surgical procedures in Australia.  
Questionable ethics and regulatory failures 
This case raises serious ethical and legal issues concerning the professional conduct of medical 
practitioners and their duty of care towards patients, the regulation of innovative therapies, and the 
global emergence of businesses marketing stem cells directly to consumers. Practitioners have 
ethical, professional, and legal duties to act in their patient’s best interests and in ways that provide 
benefit (beneficence). These obligations can conflict with the commercial imperatives and financial 
interests of private clinics and businesses that market stem cells.  
Importantly, this duty of care is in no way diminished by the provision of information to patients, or 
demands from consumers for the freedom to access innovative therapies, even if they are risky and 
are unlikely to be beneficial.(6) This means that novel medical interventions administered outside 
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the context of clinical trials should have, at least, some likelihood of benefit to justify the potential 
risks of harm. From a legal perspective, one can only consent to a serious bodily medical 
intervention when that intervention is clinically justified by, for example, there being a tangible 
therapeutic benefit. The implication is that if a medical intervention has no therapeutic benefit, it 
cannot be consented to, and any ‘informed consent’ will be vitiated. Such ‘treatments’ are regarded 
in the common law as assault and/or batteries.(7)  
This issue of informed consent was raised in the Drysdale case, with the Deputy Coroner contending 
that Dr Bright might not have fully-informed Mrs Drysdale’s husband (who was her surrogate 
decision-maker and who had himself been ‘treated’ by Dr Bright for osteoarthritis) about the lack of 
scientific evidence and justification for the intervention. Yet, even if this were not the case and Mr 
Drysdale had been fully informed of both the risks of harm from the liposuction procedure and the 
unlikelihood that the treatment would be effective for his wife’s dementia, the intervention would 
still have been clinically unjustified, morally inexcusable and legally suspect. The act of providing 
information does not, ipso facto, validate the choices of patients, nor does it remove a doctor’s duty 
of care. 
Mrs Drysdale’s death was not the first to occur in the context of unjustified and dangerous stem cell 
procedures. In 2008, an 18-month old child with cerebral palsy died in Germany following 
complications of a procedure in which autologous bone marrow-derived stem cells were injected 
into the brain.(8) In 2009, a 27-year British patient died in Ecuador of intracranial hypertension 
following an unspecified stem cell procedure for his spinal injury.(9) In 2010, a 73-year old Korean 
patient died in Japan from a pulmonary embolism and another died in China following a procedure 
with autologous adipose-derived stem cells for arthritis.(10) And two patients died in Florida after 
being administered stem cells at the same clinic.(11) The first patient died in 2010 from a cerebellar 
infarct after having bone marrow-derived autologous stem cells injected into the arterial circulation 
of her brain for the ‘treatment’ of peripheral neuropathy. The other patient died in 2012 after being 
injected intravenously with autologous adipose derived stem cells for the treatment of pulmonary 
hypertension and fibrosis; he died at the clinic suffering a cardiac arrest. 
These troubling incidents are indicative of the invasive procedures that are frequently used in stem 
cell clinics, which includes intrathecal injection and intravenous infusions that are associated with 
non-trivial risks. Recent reports have identified hundreds of businesses offering such procedures in 
countries with diverse economies and infrastructure for regulating the claims and conduct of 
medical professionals. This includes the United States,(12) Japan,(13) Australia,(14) as well as China, 
Mexico, India and many more.(15-17) These clinics often form loose collaborative networks to 
exploit weaknesses and loopholes in regulations across different geographic jurisdictions,(18) and 
wilfully misinterpret imprecise definitions and vagaries in laws that regulate the manufacturing and 
marketing of human cells for medical purposes.(19) In Australia, for example, a regulatory ‘loophole’ 
that explicitly excludes autologous cellular therapies from regulation as biological drugs (14) helped 
to create the context in which Mrs Drysdale’s death occurred.  
In addition to taking advantage of regulatory loopholes, it appears that doctors offering autologous 
stem cells outside the context of clinical trials may also be deliberately misconstruing laws that 
distinguish medical practice from clinical research and innovation.(19) Although porous distinctions 
between clinical practice and research may offer a degree of regulatory flexibility and potentially 
promote worthwhile innovation, they also provide opportunities for doctors to administer unproven 
and unjustified interventions to highly vulnerable patients under the guise of ‘innovation’ without 
any of the oversight provisions given to participants in formal clinical research.  
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Conclusion: weak regulation, pseudo-science and bad medicine  
While innovation is an important and desirable goal in the clinical sector, it is clear that weakly 
regulated innovation has pernicious consequences. Unprincipled practitioners can readily evoke the 
language of innovation and a patient’s ‘right to choose’, and interpret poorly framed and weakly 
enforced regulation tendentiously in a bid to avoid oversight from within the domains of either 
clinical care or human subject research.  This lack of oversight has resulted in a range of avoidable 
harms, ranging from the financial and psychological burden of failed treatments, to physical harm, 
illness and even death (20, 21). 
While patients bear the greatest risks of weak regulation, the emergence of this predatory sector 
also harms legitimate stem cell innovation. Stem cell research has always been a controversial field, 
and extensive community consultation and parliamentary debate has been required to establish 
legitimate forms of research and research oversight.(22) Avoidable deaths from what are marketed 
as stem cell treatments risks a withdrawal of public trust from the entire sector, with potentially 
serious consequences for research funding and regulatory initiatives that might otherwise help 
promote innovative stem cell therapies.  
The values of Responsible Research and Innovation (RRI) that form the centrepiece of the European 
Commission’s Science Research funding system can be evoked in this context. RRI approaches 
advocate social deliberation and careful risk-benefit assessment to underpin the ‘ethical 
acceptability, sustainability and societal desirability of the innovation process and its marketable 
products’.(23) Such an approach is essential if true stem cell innovation is to result in safe, 
beneficent treatments. Clinicians and regulators should recognise Mrs Drysdale’s death, and others 
that preceded it, as a tipping point towards best practice, and ethical and responsible innovation. If 
not, we can expect that Sheila Drysdale’s entirely preventable death will not be the last such tragedy.  
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